Vertex is currently launching Casgevy for sickle cell disease (SCD). This is a 60/40 program partnered with CRISPR ...

The $5.3m seed funding will enable clock.bio to develop its atlas of rejuvenation factors and will also enable next steps in ...

In the debate over artificial general intelligence, it’s often the “doomers” ( Eliezer Yudkowsky) or showmen (OpenAI CEO Sam ...

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...

CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

Transplanting genetically engineered OPCs, which give rise to myelin-making cells, boosted myelin repair in mice with brain ...

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...